A Randomized, Double-Blind, Placebo-Controlled, Add-on Therapy Study of Xeomin (Incobotulinumtoxina) Versus Placebo in the Treatment of Trigeminal Neuralgia
Phase of Trial: Phase II
Latest Information Update: 25 May 2017
At a glance
- Drugs Botulinum toxin A (Primary)
- Indications Trigeminal neuralgia
- Focus Therapeutic Use
- Sponsors Merz Pharmaceuticals GmbH
- 19 May 2017 Status changed from recruiting to discontinued.
- 13 Jun 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 13 Jun 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017.